

Lukas Smolej

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4400790/publications.pdf>

Version: 2024-02-01

139
papers

3,178
citations

172207

29
h-index

197535

49
g-index

147
all docs

147
docs citations

147
times ranked

5406
citing authors

#	ARTICLE	IF	CITATIONS
1	Lyn Phosphorylates and Controls ROR1 Surface Dynamics During Chemotaxis of CLL Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 838871.	1.8	4
2	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of <i>WNT5A</i> promoter and undetectable expression of <i>WNT5A</i> gene. <i>Epigenetics</i> , 2022, 17, 1628-1635.	1.3	3
3	Local Wnt signalling in the asymmetric migrating vertebrate cells. <i>Seminars in Cell and Developmental Biology</i> , 2022, 125, 26-36.	2.3	5
4	LuminoCell: a versatile and affordable platform for real-time monitoring of luciferase-based reporters. <i>Life Science Alliance</i> , 2022, 5, e202201421.	1.3	3
5	Regulation of choroid plexus development and its functions. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 304.	2.4	12
6	Rituximab, Cyclophosphamide and Dexamethasone (RCD) Chemoimmunotherapy for Relapsed Chronic Lymphocytic Leukaemia. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13421.	1.7	1
7	Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2021, 193, 723-726.	1.2	1
8	Phosphorylation-induced changes in the PDZ domain of Dishevelled 3. <i>Scientific Reports</i> , 2021, 11, 1484.	1.6	2
9	Primary Cilia Formation Does Not Rely on WNT/ β -Catenin Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 623753.	1.8	10
10	Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): long-term results of project Q&Elite by the Czech CLL Study Group. <i>British Journal of Haematology</i> , 2021, 193, 769-778.	1.2	9
11	DUCT reveals architectural mechanisms contributing to bile duct recovery in a mouse model for Alagille syndrome. <i>ELife</i> , 2021, 10, .	2.8	9
12	WNT5B in Physiology and Disease. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 667581.	1.8	25
13	A cellular and spatial map of the choroid plexus across brain ventricles and ages. <i>Cell</i> , 2021, 184, 3056-3074.e21.	13.5	150
14	MEIS-WNT5A axis regulates development of fourth ventricle choroid plexus. <i>Development (Cambridge)</i> , 2021, 148, .	1.2	13
15	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021, 13, 3134.	1.7	6
16	On the road to optimized BTK inhibition in CLL. <i>Blood</i> , 2021, 137, 3313-3314.	0.6	3
17	Roles of individual human Dishevelled paralogs in the Wnt signalling pathways. <i>Cellular Signalling</i> , 2021, 85, 110058.	1.7	4
18	External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. <i>British Journal of Haematology</i> , 2021, 193, 133-137.	1.2	4

#	ARTICLE	IF	CITATIONS
19	RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy. <i>ELife</i> , 2021, 10, .	2.8	22
20	Can We Pharmacologically Target Dishevelled: The Key Signal Transducer in the Wnt Pathways?. <i>Handbook of Experimental Pharmacology</i> , 2021, 269, 117-135.	0.9	2
21	Prognostic factors affecting the outcome after allogeneic haematopoietic stem cell transplantation for myelodysplastic syndrome. <i>Leukemia Research Reports</i> , 2021, 16, 100274.	0.2	1
22	WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer. <i>Theranostics</i> , 2020, 10, 537-552.	4.6	32
23	Incidence and prognostic significance of serum immunoglobulins and paraproteins in patients with chronic lymphocytic leukaemia: another valuable piece of the puzzle. <i>British Journal of Haematology</i> , 2020, 190, 815-816.	1.2	0
24	Choroid Plexus: The Orchestrator of Long-Range Signalling Within the CNS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4760.	1.8	15
25	Targeting Casein Kinase 1 (CK1) in Hematological Cancers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9026.	1.8	42
26	The Rho guanine nucleotide exchange factor Trio is required for neural crest cell migration and interacts with Dishevelled. <i>Development (Cambridge)</i> , 2020, 147, .	1.2	8
27	Activity of Smurf2 Ubiquitin Ligase Is Regulated by the Wnt Pathway Protein Dishevelled. <i>Cells</i> , 2020, 9, 1147.	1.8	13
28	Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The <sc>GOâ€¢CLEAR</sc> Study by the Czech <sc>CLL</sc> Study Group. <i>Hematological Oncology</i> , 2020, 38, 509-516.	0.8	7
29	Protease associated domain of RNF43 is not necessary for the suppression of Wnt/ β -catenin signaling in human cells. <i>Cell Communication and Signaling</i> , 2020, 18, 91.	2.7	14
30	CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells. <i>PLoS ONE</i> , 2020, 15, e0229170.	1.1	15
31	<sc>RNF</sc> 43 truncations trap <sc>CK</sc> 1 to drive niche-independent self-renewal in cancer. <i>EMBO Journal</i> , 2020, 39, e103932.	3.5	31
32	Mutations in GRK2 cause Jeune syndrome by impairing Hedgehog and canonical Wnt signaling. <i>EMBO Molecular Medicine</i> , 2020, 12, e11739.	3.3	16
33	Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia. <i>Lancet Oncology</i> , The, 2019, 20, 1478-1479.	5.1	1
34	Experiences in the treatment of refractory chylothorax associated with lymphoproliferative disorders. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 9.	1.2	9
35	Dishevelled-3 conformation dynamics analyzed by FRET-based biosensors reveals a key role of casein kinase 1. <i>Nature Communications</i> , 2019, 10, 1804.	5.8	20
36	Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLLâ€¢a maintenance trial. <i>Cancer Medicine</i> , 2019, 8, 1401-1405.	1.3	7

#	ARTICLE	IF	CITATIONS
37	WNT5A is transported via lipoprotein particles in the cerebrospinal fluid to regulate hindbrain morphogenesis. <i>Nature Communications</i> , 2019, 10, 1498.	5.8	64
38	TEM ExosomeAnalyzer: a computer-assisted software tool for quantitative evaluation of extracellular vesicles in transmission electron microscopy images. <i>Journal of Extracellular Vesicles</i> , 2019, 8, 1560808.	5.5	36
39	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019, 79, 17-21.	0.4	7
40	Single-agent ibrutinib in RESONATE-2 and RESONATE versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2019, 98, 2749-2760.	0.8	9
41	Comparative phosphorylation map of Dishevelled 3 links phospho-signatures to biological outputs. <i>Cell Communication and Signaling</i> , 2019, 17, 170.	2.7	22
42	Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study. <i>Blood Cancer Journal</i> , 2019, 9, 98.	2.8	11
43	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study. <i>Haematologica</i> , 2018, 103, 1209-1217.	1.7	30
44	Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia. <i>Blood</i> , 2018, 131, 1206-1218.	0.6	39
45	Mouse Model of Alagille Syndrome and Mechanisms of Jagged1 Missense Mutations. <i>Gastroenterology</i> , 2018, 154, 1080-1095.	0.6	92
46	Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, 313-324.	1.7	16
47	The planar cell polarity protein VANG-1/Vangl negatively regulates Wnt/ β -catenin signaling through a Dvl dependent mechanism. <i>PLoS Genetics</i> , 2018, 14, e1007840.	1.5	29
48	Dishevelled enables casein kinase 1-mediated phosphorylation of Frizzled 6 required for cell membrane localization. <i>Journal of Biological Chemistry</i> , 2018, 293, 18477-18493.	1.6	13
49	Analysis of binding interfaces of the human scaffold protein AXIN1 by peptide microarrays. <i>Journal of Biological Chemistry</i> , 2018, 293, 16337-16347.	1.6	16
50	Dishevelled has a YAP nuclear export function in a tumor suppressor context-dependent manner. <i>Nature Communications</i> , 2018, 9, 2301.	5.8	55
51	Role of ofatumumab (OFA) maintenance treatment in relapsed chronic lymphocytic leukemia (CLL): Final analysis of PROLONG study. <i>Journal of Clinical Oncology</i> , 2018, 36, 7517-7517.	0.8	1
52	COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. <i>Leukemia and Lymphoma</i> , 2017, 58, 70-79.	0.6	14
53	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. <i>Leukemia and Lymphoma</i> , 2017, 58, 348-356.	0.6	3
54	Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. <i>Lancet Oncology</i> , 2017, 18, 297-311.	5.1	219

#	ARTICLE	IF	CITATIONS
55	The connections of Wnt pathway components with cell cycle and centrosome: side effects or a hidden logic?. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2017, 52, 614-637.	2.3	51
56	Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. <i>British Journal of Pharmacology</i> , 2017, 174, 4701-4715.	2.7	45
57	WNT signalling: mechanisms and therapeutic opportunities. <i>British Journal of Pharmacology</i> , 2017, 174, 4543-4546.	2.7	8
58	The tyrosine Y2502.39 in Frizzled 4 defines a conserved motif important for structural integrity of the receptor and recruitment of Disheveled. <i>Cellular Signalling</i> , 2017, 38, 85-96.	1.7	16
59	The N-Terminal Part of the Dishevelled DEP Domain Is Required for Wnt/ β -Catenin Signaling in Mammalian Cells. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	34
60	Management of chronic lymphocytic leukemia (CLL) in the elderly: a position paper from an international Society of Geriatric Oncology (SIOG) Task Force. <i>Annals of Oncology</i> , 2017, 28, 218-227.	0.6	77
61	Angled Growth of the Dental Lamina Is Accompanied by Asymmetrical Expression of the WNT Pathway Receptor Frizzled 6. <i>Frontiers in Physiology</i> , 2017, 8, 29.	1.3	9
62	Antibodies against Pneumococcal Capsular Polysaccharides and Natural Anti-Galactosyl (Alpha-Gal) in Patients with Humoral Immunodeficiencies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	5
63	The natural compound Jatrophone interferes with Wnt/ β -catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. <i>PLoS ONE</i> , 2017, 12, e0189864.	1.1	46
64	A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. <i>Molecular Neurodegeneration</i> , 2017, 12, 54.	4.4	44
65	Comparative cell cycle transcriptomics reveals synchronization of developmental transcription factor networks in cancer cells. <i>PLoS ONE</i> , 2017, 12, e0188772.	1.1	22
66	Treatment of elderly and comorbid patients with chronic lymphocytic leukemia. <i>Onkologie (Czech)</i> Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.0	0
67	Practical approach to management of chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 448-456.	0.4	5
68	Five years of experience with rituximab plus high-dose dexamethasone for relapsed/refractory chronic lymphocytic leukemia. <i>Archives of Medical Science</i> , 2016, 2, 421-427.	0.4	8
69	Dishevelled is a NEK2 kinase substrate controlling dynamics of centrosomal linker proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 9304-9309.	3.3	55
70	ROR β -based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. <i>British Journal of Haematology</i> , 2016, 175, 339-342.	1.2	6
71	Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. <i>British Journal of Haematology</i> , 2016, 175, 851-859.	1.2	13
72	Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Maintenance randomised trial. <i>Lancet Haematology</i> , 2016, 3, e317-e329.	2.2	42

#	ARTICLE	IF	CITATIONS
73	Automatic Detection and Segmentation of Exosomes in Transmission Electron Microscopy. Lecture Notes in Computer Science, 2016, , 318-325.	1.0	3
74	A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL. American Journal of Hematology, 2016, 91, 900-906.	2.0	22
75	Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 459-469.	3.2	47
76	Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells. Oncotarget, 2016, 7, 62091-62106.	0.8	19
77	Therapeutic Approach to Patients with Chronic Lymphocytic Leukemia and Significant Comorbid Conditions. Current Cancer Drug Targets, 2016, 16, 710-720.	0.8	6
78	Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge. Current Cancer Drug Targets, 2016, 16, 701-709.	0.8	7
79	Simplified protocol for flow cytometry analysis of fluorescently labeled exosomes and microvesicles using dedicated flow cytometer. Journal of Extracellular Vesicles, 2015, 4, 25530.	5.5	287
80	Ofatumumab retreatment and maintenance in fludarabineâ€refractory chronic lymphocytic leukaemia patients. British Journal of Haematology, 2015, 170, 40-49.	1.2	14
81	Ovarian carcinoma CDK12 mutations misregulate expression of DNA repair genes via deficient formation and function of the Cdk12/CycK complex. Nucleic Acids Research, 2015, 43, 2575-2589.	6.5	107
82	Fibroblast growth factor and canonical WNT/Î²-catenin signaling cooperate in suppression of chondrocyte differentiation in experimental models of FGFR signaling in cartilage. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2015, 1852, 839-850.	1.8	56
83	Prothrombotic changes due to an increase in thyroid hormone levels. European Journal of Endocrinology, 2015, 172, 537-542.	1.9	43
84	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a Phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. Haematologica, 2015, 100, 511-516.	1.7	42
85	Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. American Journal of Hematology, 2015, 90, 417-421.	2.0	18
86	Venous thromboembolism in patients with chronic lymphocytic leukemia. Thrombosis Research, 2015, 136, 1082-1086.	0.8	19
87	Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncology, The, 2015, 16, 1370-1379.	5.1	105
88	Ten yearsâ€™ experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study. Leukemia and Lymphoma, 2015, 56, 2013-2018.	0.6	4
89	Outcome of Patients with Hodgkin Lymphoma transformed from Chronic Lymphocytic Leukemia. Blood, 2015, 126, 5298-5298.	0.6	0
90	Î²-Arrestin Interacts with the Beta/Gamma Subunits of Trimeric G-Proteins and Dishevelled in the Wnt/Ca2+ Pathway in Xenopus Gastrulation. PLoS ONE, 2014, 9, e87132.	1.1	16

#	ARTICLE	IF	CITATIONS
91	Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 8, 1.	0.4	4
92	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. <i>Neoplasma</i> , 2014, 62, 585-592.	0.7	4
93	Functional Analysis of Dishevelled-3 Phosphorylation Identifies Distinct Mechanisms Driven by Casein Kinase 1 μ and Frizzled5. <i>Journal of Biological Chemistry</i> , 2014, 289, 23520-23533.	1.6	50
94	Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Maintenance Trial. <i>Blood</i> , 2014, 124, 20-20.	0.6	8
95	Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results. <i>Blood</i> , 2014, 124, 21-21.	0.6	26
96	Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group. <i>Blood</i> , 2014, 124, 4670-4670.	0.6	16
97	Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. <i>Annals of Oncology</i> , 2013, 24, 2119-2123.	0.6	107
98	The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. <i>European Journal of Haematology</i> , 2013, 90, 479-485.	1.1	11
99	A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study. <i>Blood</i> , 2013, 122, 1645-1645.	0.6	2
100	Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life. <i>Blood</i> , 2013, 122, 2877-2877.	0.6	15
101	The role of high-dose corticosteroids in the treatment of chronic lymphocytic leukemia. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1009-1017.	1.9	14
102	Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia. <i>Hematology</i> , 2012, 17, 268-274.	0.7	8
103	Therapy of Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia. <i>Current Pharmaceutical Design</i> , 2012, 18, 3399-3405.	0.9	16
104	Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2012, 36, 1278-1282.	0.4	25
105	The Fate of Chronic Lymphocytic Leukemia Patients After Failure of Fludarabine, Cyclophosphamide, and Rituximab Regimen. <i>Blood</i> , 2012, 120, 4603-4603.	0.6	0
106	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 6450-6458.	0.6	121
107	Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells. <i>Neoplasma</i> , 2011, 58, 140-145.	0.7	8
108	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , 2011, 117, 1817-1821.	0.6	37

#	ARTICLE	IF	CITATIONS
109	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. <i>European Journal of Haematology</i> , 2011, 87, 130-137.	1.1	15
110	A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: Analysis of 1287 diagnostic and 1148 follow-up CLL samples. <i>Leukemia Research</i> , 2011, 35, 889-898.	0.4	14
111	Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. <i>Blood</i> , 2011, 118, 1793-1793.	0.6	2
112	Five-Color Multiplex Real-Time PCR Technology to Detect Over 75 Recurrent Chromosomal Abnormalities in Acute Myeloid Leukemia; Benefits for Minimal Residual Disease Detection. <i>Blood</i> , 2011, 118, 2526-2526.	0.6	2
113	Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2010, 84, 513-517.	1.1	8
114	Severe anemia caused by combination of autoimmune hemolysis, pure red cell aplasia and massive bone marrow infiltration in an elderly patient with chronic lymphocytic leukemia: Successful treatment with rituximab. <i>Leukemia Research</i> , 2010, 34, e140-e141.	0.4	1
115	Diffuse large B-cell lymphoma in a patient with hyper-IgE syndrome: Successful treatment with risk-adapted rituximab-based immunochemotherapy. <i>Leukemia Research</i> , 2010, 34, e232-e234.	0.4	15
116	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. <i>Hematology</i> , 2010, 15, 210-214.	0.7	8
117	Ofatumumab Combined With Fludarabine and Cyclophosphamide (O-FC) Shows High Activity in Patients With Previously Untreated Chronic Lymphocytic Leukemia: Results From a Randomized, Multicenter, International, Two-Dose, Parallel-Group Phase II Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, E33-E34.	0.2	11
118	Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group. <i>Blood</i> , 2010, 116, 2466-2466.	0.6	6
119	How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. <i>Acta Medica (Hradec) Tj ETQq1 1 0.784314 rgBT /Over</i>	0.2	5
120	Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010, 116, 4629-4629.	0.6	0
121	Modern concepts in the treatment of chronic lymphocytic leukemia. <i>Hematology</i> , 2009, 14, 249-254.	0.7	6
122	Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2008, 32, 395-400.	0.4	7
123	Choice of endothelial marker is crucial for assessment of bone marrow microvessel density in chronic lymphocytic leukemia. <i>Apmis</i> , 2008, 116, 1058-1062.	0.9	7
124	Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease. <i>International Journal of Laboratory Hematology</i> , 2008, 30, 259-260.	0.7	5
125	Efficacy of pneumococcal vaccination in chronic lymphocytic leukemia: Should we rely on surrogate markers?. <i>Vaccine</i> , 2008, 26, 1407.	1.7	3
126	Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. <i>Atherosclerosis</i> , 2008, 197, 264-270.	0.4	36

#	ARTICLE	IF	CITATIONS
127	Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?. <i>Blood</i> , 2008, 112, 2167-2167.	0.6	4
128	Delta Ex6, the Novel Transactivation-Defective Splicing Variant of p53 Gene, Is Differentially Expressed in Patients with Chronic Lymphocytic Leukemia and Confers Accented Proliferative Phenotype in Vitro. <i>Blood</i> , 2008, 112, 3795-3795.	0.6	0
129	Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using Locked Nucleic Acid-Modified, Fluorescently Labeled Hybridization Probes and Real-Time PCR Technology. <i>Molecular Diagnosis and Therapy</i> , 2007, 11, 325-335.	1.6	3
130	Fludarabine-induced autoimmune hemolytic anemia in a CLL patient: Rituximab as the treatment of choice?. <i>Leukemia Research</i> , 2007, 31, 267.	0.4	2
131	Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: More data needed. <i>Leukemia Research</i> , 2007, 31, 1763-1764.	0.4	4
132	Why R-CHOP for first line treatment of chronic lymphocytic leukemia?. <i>International Journal of Laboratory Hematology</i> , 2007, 29, 478-479.	0.7	0
133	The prognostic role of CLLU1 in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2006, 77, 177-177.	1.1	2
134	Role of angiogenesis in chronic lymphocytic leukemia. <i>Cancer</i> , 2006, 107, 2742-2743.	2.0	1
135	Quantitation of Minimal Residual Disease in Patients with Chronic Lymphocytic Leukemia Using LNA-Modified Fluorescently Labeled Probes and Real-Time PCR Technology.. <i>Blood</i> , 2006, 108, 2331-2331.	0.6	0
136	Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. <i>Haematologica</i> , 2006, 91, 1432-3.	1.7	8
137	Plasma Concentrations of Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor in Lymphoproliferative Disorders. <i>Acta Medica (Hradec Kralove)</i> , 2005, 48, 57-58.	0.2	14
138	Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. <i>Acta Medica (Hradec Kralove)</i> , 2005, 48, 57-8.	0.2	10
139	The reverse tetracycline-controlled transactivator rtTA2S-S2 is toxic in mouse embryonic stem cells. <i>Reproduction, Nutrition, Development</i> , 2003, 43, 477-486.	1.9	7